Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Hierarchical Treatment for Rectal Cancer
NCT03071198Unknown
- Sponsor
- Harbin Medical University
- Start
- Mar 2017
- Primary completion
- Sep 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of oxaliplatin and capecitabine in rectal cancer (3 arms), sponsored by Harbin Medical University. Primary endpoint: Disease Free Survival at 3 years. Status: unknown.
02
Drugs
oxaliplatincapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03071198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071198.